Wharton's Jelly derived Mesenchymal stem cell therapy (Medical University Of Gdansk)

N/A

Report date: 2024/11/26 11:55:49

Base Information

Drug NameWharton's Jelly derived Mesenchymal stem cell therapy (Medical University Of Gdansk)

Drug Alias NameAllogeneic mesenchymal stem cells derived from Wharton's jelly (Medical University Of Gdansk)

ClassificationCell and gene therapy > Cell therapy > Source of cells > Wharton's Jelly-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Donor > Allogeneic

Mechanisms of ActionImmunomodulatorsStem cell replacements

TargetsUpdating

Therapy Area/IndicationsLung Diseases, Interstitial

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryPoland

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesMedical University Of Gdansk

China Registration ClassN/A

Develop Information

Active CompaniesMedical University Of Gdansk

Inactive CompaniesN/A

Active IndicationsLung Diseases, Interstitial

Inactive IndicationsN/A

Other Information

ATC CodeN/A